Industry News
Pharmaceutical Industry News
Foresee Pharmaceuticals Camcevi,…
Foresee Pharmaceuticals Camcevi, currently approved as a treatment for advanced prostate cancer, showed promise in a phase 3 study that enrolled children with central precocious puberty (CPP).
The emergence of next-generation…
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated non-small cell lung cancer following an
Although it looked to be lights…
Although it looked to be lights out for InflaRx’s C5a antibody vilobelimab in the rare skin disorder pyoderma gangrenosum last year, the German drugmaker ended 2025 with a glimmer of hope for the asset, thanks
New York to Phase In Protections for Horseshoe Crabs
Gov. Kathy Hochul signed legislation that will ultimately ban the catch and biomedical use of the crabs.
To get its hands on the…
To get its hands on the Emeryville, California-based company and its approved adult hepatitis B vaccine Heplisav-B, Sanofi will pay $15.50 per Dynavax share in cash, which works out to a total deal value of
How Cameroon Fought to Save Its Malaria Program After the U.S. Cut Critical Funding
When the Trump administration slashed foreign aid, it gutted a program that had reduced malaria deaths world wide. In northern Cameroon, health workers tried to protect children in one last rainy season.
With a Christmas Eve thumbs up for…
With a Christmas Eve thumbs up for Yartemlea, the FDA has delivered Omeros its first U.S. approval in its 31 years. Yartemlea becomes the first treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.
F.D.A. Approves Wegovy Weight-Loss Pill
The agency greenlit an oral version of the obesity drug Wegovy.
With the 10-year anniversary of…
With the 10-year anniversary of the first approved biosimilar in the rearview, the next decade will bring shifting policies, key patent cliffs and the threat of the "biosimilar void."
Of the top 10 biopharma M&A…
Of the top 10 biopharma M&A deals of 2025, six came in the fourth quarter. Will the surge continue in 2026? Many industry watchers—based on what they witnessed in Q4—believe that 2026 will be a
A court in Baltimore has ordered…
A court in Baltimore has ordered Johnson & Johnson to pay $1.56 billion to a Maryland woman who claimed that her use of the company’s baby powder caused her cancer. It is the largest award
A patient in an open label…
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has passed away, the company and several hemophilia advocacy groups confirmed this week.
Neurocrine’s Ingrezza, approved…
Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to move the needle in a phase 3 trial in patients with dyskinesia due to cerebral palsy.
Drug pricing, layoffs, personnel…
Drug pricing, layoffs, personnel moves and other topics drove reader interest all year long. Here's a look at some of our top stories from the year.
Pharma giant AstraZeneca extended…
Pharma giant AstraZeneca extended its supply deal with Michigan-based medical radioisotope producer Niowave by 10 years, teeing up the delivery of Actinium-225 that has shown promise as a component in targeted cancer therapy.
CMS’ Innovation Center has…
CMS' Innovation Center has released two new drug pricing models that base rebates on international drug prices, which are significantly lower than what U.S. consumers pay for the same products.
Boehringer’s Jascayd can now crack…
Boehringer's Jascayd can now crack open the rare progressive pulmonary fibrosis disease market just two months after its initial market entry in idiopathic pulmonary fibrosis.
Slated for a Dec. 26 decision on…
Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the biotech its first U.S. nod since it was established in 1997. The agency has signed off
A six-month community awareness…
A six-month community awareness campaign has significantly increased colorectal cancer awareness in part of Nigeria, leading researchers to recommend expanding the model to the national level.
The acquisition will allow…
The acquisition will allow Shionogi to add a "strong rare disease commercial platform in the U.S. market," potentially supporting its planned launches in Fragile X syndrome, Jordan’s Syndrome and Pompe disease, the company said.